267 related articles for article (PubMed ID: 23286293)
21. Inhibition of Xanthine Oxidase Protects against Diabetic Kidney Disease through the Amelioration of Oxidative Stress via VEGF/VEGFR Axis and NOX-FoxO3a-eNOS Signaling Pathway.
Yang KJ; Choi WJ; Chang YK; Park CW; Kim SY; Hong YA
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835220
[TBL] [Abstract][Full Text] [Related]
22. The xanthine oxidase inhibitor Febuxostat reduces tissue uric acid content and inhibits injury-induced inflammation in the liver and lung.
Kataoka H; Yang K; Rock KL
Eur J Pharmacol; 2015 Jan; 746():174-9. PubMed ID: 25449036
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of Xanthine Oxidase Protects against Sepsis-Induced Acute Kidney Injury by Ameliorating Renal Hypoxia.
Wang TT; Du YW; Wang W; Li XN; Liu HB
Oxid Med Cell Longev; 2022; 2022():4326695. PubMed ID: 35873795
[TBL] [Abstract][Full Text] [Related]
24. Febuxostat attenuates paroxysmal atrial fibrillation-induced regional endothelial dysfunction.
Li Y; Chen F; Deng L; Lin K; Shi X; Zhaoliang S; Wang Y
Thromb Res; 2017 Jan; 149():17-24. PubMed ID: 27865966
[TBL] [Abstract][Full Text] [Related]
25. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Ernst ME; Fravel MA
Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
[TBL] [Abstract][Full Text] [Related]
26. Xanthine Oxidase Inhibitor Febuxostat Exerts an Anti-Inflammatory Action and Protects against Diabetic Nephropathy Development in KK-Ay Obese Diabetic Mice.
Mizuno Y; Yamamotoya T; Nakatsu Y; Ueda K; Matsunaga Y; Inoue MK; Sakoda H; Fujishiro M; Ono H; Kikuchi T; Takahashi M; Morii K; Sasaki K; Masaki T; Asano T; Kushiyama A
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31546603
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of xanthine oxidase in the acute phase of myocardial infarction prevents skeletal muscle abnormalities and exercise intolerance.
Nambu H; Takada S; Maekawa S; Matsumoto J; Kakutani N; Furihata T; Shirakawa R; Katayama T; Nakajima T; Yamanashi K; Obata Y; Nakano I; Tsuda M; Saito A; Fukushima A; Yokota T; Nio-Kobayashi J; Yasui H; Higashikawa K; Kuge Y; Anzai T; Sabe H; Kinugawa S
Cardiovasc Res; 2021 Feb; 117(3):805-819. PubMed ID: 32402072
[TBL] [Abstract][Full Text] [Related]
28. Xanthine oxidase inhibitor febuxostat reduces atrial fibrillation susceptibility by inhibition of oxidized CaMKII in Dahl salt-sensitive rats.
Xu D; Murakoshi N; Tajiri K; Duo F; Okabe Y; Murakata Y; Yuan Z; Li S; Aonuma K; Song Z; Shimoda Y; Mori H; Sato A; Nogami A; Aonuma K; Ieda M
Clin Sci (Lond); 2021 Oct; 135(20):2409-2422. PubMed ID: 34386810
[TBL] [Abstract][Full Text] [Related]
29. Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice.
Nishikawa T; Nagata N; Shimakami T; Shirakura T; Matsui C; Ni Y; Zhuge F; Xu L; Chen G; Nagashimada M; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S; Ota T
Sci Rep; 2020 Jan; 10(1):815. PubMed ID: 31965018
[TBL] [Abstract][Full Text] [Related]
30. The Xanthine Oxidase Inhibitor Febuxostat Suppresses the Progression of IgA Nephropathy, Possibly via Its Anti-Inflammatory and Anti-Fibrotic Effects in the gddY Mouse Model.
Inoue MK; Yamamotoya T; Nakatsu Y; Ueda K; Inoue Y; Matsunaga Y; Sakoda H; Fujishiro M; Ono H; Morii K; Sasaki K; Masaki T; Suzuki Y; Asano T; Kushiyama A
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544662
[TBL] [Abstract][Full Text] [Related]
31. Febuxostat exerts dose-dependent renoprotection in rats with cisplatin-induced acute renal injury.
Fahmi AN; Shehatou GS; Shebl AM; Salem HA
Naunyn Schmiedebergs Arch Pharmacol; 2016 Aug; 389(8):819-30. PubMed ID: 27215580
[TBL] [Abstract][Full Text] [Related]
32. Xanthine oxidase inhibitors beyond allopurinol and febuxostat; an overview and selection of potential leads based on in silico calculated physico-chemical properties, predicted pharmacokinetics and toxicity.
Šmelcerović A; Tomović K; Šmelcerović Ž; Petronijević Ž; Kocić G; Tomašič T; Jakopin Ž; Anderluh M
Eur J Med Chem; 2017 Jul; 135():491-516. PubMed ID: 28478180
[TBL] [Abstract][Full Text] [Related]
33. A new xanthine oxidase inhibitor: the uric acid reduction and additional efficacy in CKD patients.
Ohya M; Shigematsu T
Clin Exp Nephrol; 2014 Dec; 18(6):835-6. PubMed ID: 24871070
[No Abstract] [Full Text] [Related]
34. Xanthine Oxidase Drives Hemolysis and Vascular Malfunction in Sickle Cell Disease.
Schmidt HM; Wood KC; Lewis SE; Hahn SA; Williams XM; McMahon B; Baust JJ; Yuan S; Bachman TN; Wang Y; Oh JY; Ghosh S; Ofori-Acquah SF; Lebensburger JD; Patel RP; Du J; Vitturi DA; Kelley EE; Straub AC
Arterioscler Thromb Vasc Biol; 2021 Feb; 41(2):769-782. PubMed ID: 33267657
[TBL] [Abstract][Full Text] [Related]
35. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.
Bruce SP
Ann Pharmacother; 2006 Dec; 40(12):2187-94. PubMed ID: 17132810
[TBL] [Abstract][Full Text] [Related]
36. Febuxostat, a nonpurine selective inhibitor of xanthine oxidase: a promising medical therapy for chronic heart failure?
Gao LG; Yao XP; Zhang L; Wen D; Luo F; Zhou XL; Hui RT
Chin Med J (Engl); 2010 Sep; 123(17):2471-4. PubMed ID: 21034568
[No Abstract] [Full Text] [Related]
37. The Effect of Xanthine Oxidase Inhibitors on Blood Pressure and Renal Function.
Bove M; Cicero AFG; Borghi C
Curr Hypertens Rep; 2017 Oct; 19(12):95. PubMed ID: 29071435
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in kidney transplant recipients.
Tojimbara T; Nakajima I; Yashima J; Fuchinoue S; Teraoka S
Transplant Proc; 2014; 46(2):511-3. PubMed ID: 24656001
[TBL] [Abstract][Full Text] [Related]
39. Xanthine Oxidoreductase Is Involved in Chondrocyte Mineralization and Expressed in Osteoarthritic Damaged Cartilage.
Nasi S; Castelblanco M; Chobaz V; Ehirchiou D; So A; Bernabei I; Kusano T; Nishino T; Okamoto K; Busso N
Front Cell Dev Biol; 2021; 9():612440. PubMed ID: 33634117
[TBL] [Abstract][Full Text] [Related]
40. Natural Products and Extracts as Xantine Oxidase Inhibitors - A Hope for Gout Disease?
Orhan IE; Deniz FSS
Curr Pharm Des; 2021; 27(2):143-158. PubMed ID: 32723252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
